Grants and Contributions:
The direct and immediate benefit of the project's first stage is the rapid development of a plant-based vaccine that may lead to an effective vaccine for COVID-19, and thus, help prevent the spread. The second stage, building a GMP facility that can manufacture vaccine and antibodies, is expected to increase biomanufacturing capabilities and build on areas of strength and technological advantage to advance Canada’s life science’s industry.
This is a repayable contribution.
The Strategic Innovation Fund (SIF) attracts and supports new high-quality business investments. In allocating funding, SIF looks to accelerate areas of economic strength, strengthen and expand the role of Canadian firms in regional and global supply chains, support economic strategies, and attract investment that creates new, good, well-paying jobs.